We are live on
!
Find out more
Loomis, Sayles & Company Portfolio holdings
AUM
$74.3B
1-Year Est. Return
24.01%
This Fund
S&P 500
This Quarter
Est. Return
+5.89%
1 Year Est. Return
+24.01%
3 Year Est. Return
+109.67%
5 Year Est. Return
+145.58%
10 Year Est. Return
+623.12%
AUM
$53.6B
AUM Growth
+$2.66B
(+5.2%)
Cap. Flow
+$86.8M
Cap. Flow
% of AUM
0.16%
Top 10 Holdings %
Top 10 Hldgs %
37.17%
Holding
821
New
56
Increased
227
Reduced
258
Closed
253
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$86.2M |
| 2 |
Alcon
ALC
|
+$81.8M |
| 3 |
NVIDIA
NVDA
|
+$76M |
| 4 |
Corning
GLW
|
+$50.4M |
| 5 |
UnitedHealth
UNH
|
+$42.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Novartis
NVS
|
+$67.4M |
| 2 |
Factset
FDS
|
+$62M |
| 3 |
Euronet Worldwide
EEFT
|
+$42.3M |
| 4 |
Bank of America Series L
BAC.PRL
|
+$39.5M |
| 5 |
OPLN
Openlane
OPLN
|
+$31.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.75% |
| 2 | Consumer Discretionary | 17.74% |
| 3 | Financials | 11.65% |
| 4 | Healthcare | 11.2% |
| 5 | Communication Services | 10.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
226
West Pharmaceutical
WST
$24.9B
| $16M | 0.03% |
127,725
+9,656
| +8% | +$1.14M |
|
|
ZEN
227
DELISTED
ZENDESK INC
ZEN
| $15.9M | 0.03% |
178,772
-10,827
| -6% | -$931K |
|
|
WBC
228
DELISTED
WABCO HOLDINGS INC.
WBC
| $15.8M | 0.03% |
118,784
-7,209
| -6% | -$951K |
|
229
First American
FAF
$7.58B
| $15.7M | 0.03% |
292,751
+15,197
| +5% | +$827K |
|
|
FLIR
230
DELISTED
FLIR Systems, Inc. (DE) Common Stock
FLIR
| $15.7M | 0.03% |
290,061
+4,471
| +2% | +$227K |
|
231
Synopsys
SNPS
$79.7B
| $15.6M | 0.03% |
121,522
-41,811
| -26% | -$5.03M |
|
232
Ciena
CIEN
$58.4B
| $15.6M | 0.03% |
380,179
-22,999
| -6% | -$885K |
|
233
Ziff Davis
ZD
$1.98B
| $15.6M | 0.03% |
201,566
-27,774
| -12% | -$2.1M |
|
234
Kemper
KMPR
$1.68B
| $15.5M | 0.03% |
179,847
-10,896
| -6% | -$931K |
|
|
AIMT
235
DELISTED
Aimmune Therapeutics
AIMT
| $15.4M | 0.03% |
737,626
+170,692
| +30% | +$3.51M |
|
236
Rexford Industrial Realty
REXR
$8.19B
| $15.2M | 0.03% |
375,764
-38,037
| -9% | -$1.45M |
|
237
Nasdaq
NDAQ
$52.9B
| $14.9M | 0.03% |
465,381
-23,715
| -5% | -$727K |
|
|
SF
238
Stifel
SF
$12.6B
| $14.9M | 0.03% |
567,322
-53,039
| -9% | -$1.35M |
|
239
Columbus McKinnon
CMCO
$584M
| $14.8M | 0.03% |
351,640
-17,904
| -5% | -$681K |
|
240
Casey's General Stores
CASY
$30.9B
| $14.8M | 0.03% |
94,568
+18,194
| +24% | +$2.48M |
|
241
DMC Global
BOOM
$157M
| $14.7M | 0.03% |
+232,741
| New | +$15.4M |
|
|
IBKC
242
DELISTED
IBERIABANK Corp
IBKC
| $14.7M | 0.03% |
193,667
-14,934
| -7% | -$1.13M |
|
243
Cannae Holdings
CNNE
$649M
| $14.6M | 0.03% |
502,719
-22,315
| -4% | -$588K |
|
|
MLNX
244
DELISTED
Mellanox Technologies, Ltd.
MLNX
| $14.5M | 0.03% |
131,309
-48,050
| -27% | -$5.54M |
|
|
PRO
245
DELISTED
PROS Holdings
PRO
| $14.5M | 0.03% |
+228,832
| New | +$12M |
|
246
Travel + Leisure Co
TNL
$4.7B
| $14.3M | 0.03% |
326,811
+71,816
| +28% | +$3.06M |
|
247
J&J Snack Foods
JJSF
$1.71B
| $14.2M | 0.03% |
88,484
-4,414
| -5% | -$705K |
|
|
AAN.A
248
DELISTED
The Aaron's Company Inc Class A
AAN.A
| $14.2M | 0.03% |
230,451
-3,864
| -2% | -$237K |
|
249
Keysight
KEYS
$58.3B
| $14.1M | 0.03% |
156,748
-44,835
| -22% | -$3.81M |
|
250
Morningstar
MORN
$7.53B
| $14M | 0.03% |
96,512
+30,441
| +46% | +$4.2M |
|
Similar funds
CBU
BC
Loomis, Sayles & Company's Q2 2019 Portfolio in Review
As of Q2 2019, Loomis, Sayles & Company held 821 positions worth $53.6B, up 5.2% from $50.9B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Loomis, Sayles & Company's Q2 2019 filing shows 56 new, 227 increased, 258 reduced and 253 closed positions. Its largest new stake was Alcon: 1,393,674 shares worth $86.5M. The largest sale was Novartis, an estimated $67.4M.
By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 20% a quarter earlier, followed by Consumer Discretionary and Financials.
- Loomis, Sayles & Company's largest Q2 2019 buy was Alcon: 1,393,674 shares worth $86.5M.
- Loomis, Sayles & Company added most to Bristol-Myers Squibb in Q2 2019, an estimated $86.2M increase.
- Loomis, Sayles & Company's biggest Q2 2019 reduction was Novartis, cutting an estimated $67.4M.
- Loomis, Sayles & Company fully exited RingCentral in Q2 2019, selling an estimated $30.4M.
- Loomis, Sayles & Company's ten largest holdings make up 37% of its $53.6B portfolio in Q2 2019.
- Loomis, Sayles & Company opened 56 new positions and closed 253 in Q2 2019.
- Loomis, Sayles & Company's portfolio value rose 5.2% quarter-over-quarter to $53.6B.
Based on Loomis, Sayles & Company's 13F filing for Q2 2019, filed 14 Aug 2019.